Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement, the ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio.

Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and Company will buy Verve Therapeutics, Inc.

Eli Lilly & Co. agreed to buy Verve Therapeutics Inc., a US biotech that’s seeking to use gene editing to prevent clogged arteries, for as much as $1.3 billion.

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. The announcement of the deal ...

Eli Lilly has announced its intention to acquire Verve Therapeutics, a biotechnology company specializing in gene-editing therapies for cardiovascular diseases, in a deal valued at up to $1.3 billion.

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

WEDNESDAY, June 18, 2025 (HealthDay News) — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront.

Eli Lilly and Company says it will acquire the gene therapy start-up Verve Therapeutics for $1.3 billion. Verve’s lead drug candidate, VERVE-102, turns off the PCSK9 gene in the liver to reduce ...

Verve Therapeutics, Inc. (NASDAQ: VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and Company will buy Verve Therapeutics, Inc. (NASDAQ:VERV) for up to $1.3 ...